SPRY

ANALYST NOTE: SPRY (ARS Pharmaceuticals, Inc.) Date: 2026-06-20 Current Price: $9.65

1. Structural Readiness

State: Forming Aggressive/Pre-Breakout Entry: — (Not actionable on setup alone; requires confirmation) Breakout Level: — (Pending confirmation) Current Price: $9.65 Extension: — (Price is currently consolidating within the forming structure; no extension above entry recorded) ATR Current: 6.0% (Very High)

2. Thesis Layer

Thesis Status: Tactical / Setup-Led Macro Thesis: None. Assessment: As of 2026-06-20, SPRY is not anchored to a named secular macro thesis. It is a tactical, setup-led name. Conviction must be derived strictly from the quality of the technical setup (the forming coil) and the immediate business fundamentals regarding the commercialization of neffy. No external macro drivers (e.g., specific regulatory shifts, sector-wide M&A) are currently driving the narrative; the focus is on the execution of the commercial rollout and the structural price formation.

3. Business Overview

Company: ARS Pharmaceuticals, Inc. Industry: Healthcare / Biotechnology Business Model: Commercialization of neffy, the first and only FDA and European Commission-approved needle-free epinephrine product for the emergency treatment of Type I allergic reactions (anaphylaxis). The company operates a hybrid commercial model utilizing a direct sales force, a co-promotion agreement with ALK-Abelló, and international licensing (Japan).

Key Business Metrics (as of Q1 2026 / May 2026):

• Revenue: Generated $22.7 million in total revenue in Q1 2026, including $17.5 million in U.S. net product revenue for neffy. This represents a 3x increase in prescription volume year-over-year.
• Patient Adoption: Approximately 120,000 patients are currently using neffy in the U.S., with 29,500 new patients added in Q1 2026.
• Prescriber Base: More than 28,000 HCPs have prescribed neffy, with approximately 50% demonstrating repeat use.
• Commercial Coverage: Ended Q1 2026 with approximately 90% commercial coverage, of which 57% was without prior authorization (PA).
• Formulary Progress: As of late April 2026, an updated proposal was submitted to CVS to remove PA requirements, targeting a July 1, 2026 effective date.
• Sales Force Expansion: Expanded the U.S. sales force to 148 people in May 2026, focusing on high-volume accounts.
• International: Entered a commercial supply agreement with Alfresa in December 2025 for the Japanese market.
• Pipeline: Initiated a Phase 2b clinical trial for chronic spontaneous urticaria in Q2 2025, with interim data anticipated in H2 2026.

4. Archetype and Conviction

Archetype: Deep Value Recovery / Commercial Inflection Fit: The name fits the "Deep Value Recovery" archetype not because of traditional low P/E metrics (which are not provided), but because the stock is recovering from a pre-commercialization or early-commercialization state into a period of verified revenue growth and market penetration. The "inflection" is driven by the transition from "approval" to "scale," evidenced by the 3x YoY volume growth and the expansion of the sales force.

Conviction Stack:

• Thesis Strength: Moderate. The thesis is purely tactical and dependent on the successful execution of the commercial rollout. There is no macro tailwind to buffer execution risk.
• Evidence Quality: High. The evidence base (E1–E21) is robust, citing specific revenue figures, patient counts, and formulary progress from Q1 2026 earnings and SEC filings.
• Structural Quality: Moderate. The "Forming" coil indicates a healthy consolidation, but the lack of a confirmed breakout means the structural momentum is not yet proven.
• Setup Readiness: Partial. The setup is "Forming," meaning it is a watch-list candidate. It is not yet a "Confirmed" trade. The "Very High" ATR (6.0%) suggests that once the breakout fires, the move could be sharp, but the current volatility makes precise entry difficult without a confirmed signal.
• Rerating Potential: High, contingent on the July 1 CVS formulary approval and the continued 3x+ volume growth. The market is currently pricing in the *potential* of the commercial scale, which is being validated by the Q1 results.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Formulary Wins: Confirmation of the July 1 CVS PA removal and subsequent expansion of PA-free coverage beyond the current 57%.
• Revenue Acceleration: Q2 2026 revenue exceeding the Q1 run-rate, confirming the scalability of the 148-person sales force.

What Would Invalidate the Case:

• Commercial Setback: Failure to secure the CVS formulary approval or a significant drop in prescription volume (e.g., <2x YoY growth).
• Cash Burn: Evidence that the "12 months of cash" runway (E12) is threatened by higher-than-expected commercialization costs.

Gaps in Evidence:

• Valuation Metrics: No P/E, P/S, or EV/EBITDA data is provided in the evidence block to assess the "Deep Value" claim quantitatively.
• Profitability Timeline: While cash runway is confirmed for 12 months, there is no explicit management guidance on when the company expects to reach GAAP profitability or positive free cash flow.
• Competitive Landscape: No specific data on competitor market share or pricing pressure from traditional auto-injectors is provided in the evidence.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Q1 2026 revenue of $22.7M with 3x YoY volume growth; 120,000 patients currently using neffy; 90% commercial coverage with 57% PA-free. Key risks: Technical setup is "Forming" not "Confirmed" (no breakout yet); Very High ATR (6.0%) indicates elevated volatility risk; Heavy dependence on single product neffy commercialization success. Expected path: Management expects the CVS formulary change to take effect July 1, 2026, which should drive further volume growth; the stock likely consolidates until a confirmed breakout or a catalyst-driven move occurs. Expected horizon: 3 to 6 months for the setup to resolve (breakout or invalidation) or for the July 1 catalyst to impact volume data.